Cargando…

DeepSynergy: predicting anti-cancer drug synergy with Deep Learning

MOTIVATION: While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space. However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Preuer, Kristina, Lewis, Richard P I, Hochreiter, Sepp, Bender, Andreas, Bulusu, Krishna C, Klambauer, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925774/
https://www.ncbi.nlm.nih.gov/pubmed/29253077
http://dx.doi.org/10.1093/bioinformatics/btx806
_version_ 1783318771547504640
author Preuer, Kristina
Lewis, Richard P I
Hochreiter, Sepp
Bender, Andreas
Bulusu, Krishna C
Klambauer, Günter
author_facet Preuer, Kristina
Lewis, Richard P I
Hochreiter, Sepp
Bender, Andreas
Bulusu, Krishna C
Klambauer, Günter
author_sort Preuer, Kristina
collection PubMed
description MOTIVATION: While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space. However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinations to test, based on recently available large-scale combination screening data. Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-art model performance. However, Deep Learning has not yet been applied to drug synergy prediction, which is the approach we present here, termed DeepSynergy. DeepSynergy uses chemical and genomic information as input information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug synergies. RESULTS: DeepSynergy was compared to other machine learning methods such as Gradient Boosting Machines, Random Forests, Support Vector Machines and Elastic Nets on the largest publicly available synergy dataset with respect to mean squared error. DeepSynergy significantly outperformed the other methods with an improvement of 7.2% over the second best method at the prediction of novel drug combinations within the space of explored drugs and cell lines. At this task, the mean Pearson correlation coefficient between the measured and the predicted values of DeepSynergy was 0.73. Applying DeepSynergy for classification of these novel drug combinations resulted in a high predictive performance of an AUC of 0.90. Furthermore, we found that all compared methods exhibit low predictive performance when extrapolating to unexplored drugs or cell lines, which we suggest is due to limitations in the size and diversity of the dataset. We envision that DeepSynergy could be a valuable tool for selecting novel synergistic drug combinations. AVAILABILITY AND IMPLEMENTATION: DeepSynergy is available via www.bioinf.jku.at/software/DeepSynergy. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
format Online
Article
Text
id pubmed-5925774
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-59257742018-05-04 DeepSynergy: predicting anti-cancer drug synergy with Deep Learning Preuer, Kristina Lewis, Richard P I Hochreiter, Sepp Bender, Andreas Bulusu, Krishna C Klambauer, Günter Bioinformatics Original Papers MOTIVATION: While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space. However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinations to test, based on recently available large-scale combination screening data. Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-art model performance. However, Deep Learning has not yet been applied to drug synergy prediction, which is the approach we present here, termed DeepSynergy. DeepSynergy uses chemical and genomic information as input information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug synergies. RESULTS: DeepSynergy was compared to other machine learning methods such as Gradient Boosting Machines, Random Forests, Support Vector Machines and Elastic Nets on the largest publicly available synergy dataset with respect to mean squared error. DeepSynergy significantly outperformed the other methods with an improvement of 7.2% over the second best method at the prediction of novel drug combinations within the space of explored drugs and cell lines. At this task, the mean Pearson correlation coefficient between the measured and the predicted values of DeepSynergy was 0.73. Applying DeepSynergy for classification of these novel drug combinations resulted in a high predictive performance of an AUC of 0.90. Furthermore, we found that all compared methods exhibit low predictive performance when extrapolating to unexplored drugs or cell lines, which we suggest is due to limitations in the size and diversity of the dataset. We envision that DeepSynergy could be a valuable tool for selecting novel synergistic drug combinations. AVAILABILITY AND IMPLEMENTATION: DeepSynergy is available via www.bioinf.jku.at/software/DeepSynergy. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Oxford University Press 2018-05-01 2017-12-15 /pmc/articles/PMC5925774/ /pubmed/29253077 http://dx.doi.org/10.1093/bioinformatics/btx806 Text en © The Author(s) 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Preuer, Kristina
Lewis, Richard P I
Hochreiter, Sepp
Bender, Andreas
Bulusu, Krishna C
Klambauer, Günter
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
title DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
title_full DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
title_fullStr DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
title_full_unstemmed DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
title_short DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
title_sort deepsynergy: predicting anti-cancer drug synergy with deep learning
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925774/
https://www.ncbi.nlm.nih.gov/pubmed/29253077
http://dx.doi.org/10.1093/bioinformatics/btx806
work_keys_str_mv AT preuerkristina deepsynergypredictinganticancerdrugsynergywithdeeplearning
AT lewisrichardpi deepsynergypredictinganticancerdrugsynergywithdeeplearning
AT hochreitersepp deepsynergypredictinganticancerdrugsynergywithdeeplearning
AT benderandreas deepsynergypredictinganticancerdrugsynergywithdeeplearning
AT bulusukrishnac deepsynergypredictinganticancerdrugsynergywithdeeplearning
AT klambauergunter deepsynergypredictinganticancerdrugsynergywithdeeplearning